
Nov 15, 2026 · 31 min
Listen from 5:55
Listen at 5:55
Biotech investors weigh gene editing, MASH data and RAS risk
122 - Breaking Biotech Week End Wrap Up - Nov 14, 2026
The episode tests whether promising clinical signals can overcome safety questions, difficult treatment logistics and increasingly crowded commercial markets.
- 1Beam’s interim Ristocel data face meaningful comparisons with Casgevy and Lyfgenia, alongside substantial manufacturing and commercial hurdles.
- 2Merck’s afinopegdutide results intensify competition in MASH, while Madrigal pairs strong Rezdiffra sales with scrutiny over safety reporting.
- 3Revolution’s short-report controversy turns on interpreting adverse events in very sick patients, without dislodging Matthew’s constructive investment view.
Don't miss
Matthew argues that Revolution’s apparent adverse-event imbalance may reflect a later-line pancreatic-cancer population rather than clear treatment-related harm.
The brief
Matthew opens with a market review before focusing on three pressure points: Beam’s sickle cell readout, Merck’s MASH data and a short report targeting Revolution Medicines.
Beam’s interim Ristocel results are measured against Casgevy and Lyfgenia, but the commercial case depends on solving the logistical and manufacturing burdens of autologous gene editing.
Merck’s afinopegdutide data add another contender to MASH, while Madrigal’s Rezdiffra shows sales momentum despite a whistleblower complaint about liver-safety reporting.
The central dispute around Revolution is interpretive: do adverse-event differences signal treatment harm, or reflect the unusually ill later-line population receiving Rasonq?
Arasaka’s first-line RAS ambitions and Tango’s PRMT5 combination strategy broaden the cancer discussion, leaving Matthew constructive on Revolution despite near-term pressure.
What was said on this episode
22 statements · 13 positive · 4 negative · 1 mixed · 4 neutral
Revolution Medicines’ decline created an opportunity to buy shares.
“So it's down a little bit, but I saw it as an opportunity to take a long position.”
Listen at 1:15
Jensen Huang’s departure would challenge Nvidia’s recovery.
“losing him is going to be a challenge, I think, to get them sort of back to where they are.”
Listen at 2:33
AI hype is compressing Twist Bioscience’s market multiple.
“the multiple that the market was giving them due to the hype around AI is starting, starting to get deflated.”
Listen at 3:18
Ristocel offers limited additional benefit over Casgevy or Lyfgenia.
“the added benefit to their Ristocel treatment isn't that much better than Casgevy or Lightgenia.”
Listen at 7:52
Beam will enter sickle-cell treatment as a third market option.
“they're now going to be a sort of third option As opposed to Casgevy and LifeGenia.”
Listen at 9:33
Beam plans to file a biologics license application by end-2026.
“they're gonna be aiming to file a BLA before the year end of 2026”
Listen at 10:05
Beam may have a sickle-cell treatment marketed in 2027.
“Beam might actually have a treatment on the market in 2027”
Listen at 10:41
CRISPR development is shifting toward in-vivo applications.
“I think the whole field of CRISPR is moving in vivo.”
Listen at 11:54
Merck is likely to advance afinopegdutide at seven milligrams.
“It's likely that they're gonna move forward with a 7 milligram dose instead of the 10.”
Listen at 15:49
Merck’s afinopegdutide data is slightly better than Inventiva’s data.
“So overall data is very impressive. I think it's slightly better than the Inventiva data.”
Listen at 15:58
Madrigal is currently the preferred MASH investment.
“I feel like right now Madrigal is the one to bet on.”
Listen at 18:24
A major undiscovered Rezdiffra liver-safety signal is unlikely.
“if there was a very important liver safety signal to come out, It would've come out in the phase 3. It would've come out in the real-world data by now.”
Listen at 19:40
The Rezdiffra whistleblower complaint is not a reason to sell Madrigal.
“I don't think it's a reason to sell the stock”
Listen at 20:13
Early Revolution Medicines safety signals may be statistical noise.
“any signals that we're seeing right now may just be noise.”
Listen at 21:51
Sicker patients’ deaths do not establish that Rasonq caused them.
“I don't know if you can conclude from that, that if more sick patients happen to take Rasonq, that it was necessarily Rasonq that led to their demise.”
Listen at 22:11
Revolution Medicines remains a pioneer in RAS-mediated cancer treatment.
“I still see RevMed as being, you know, the pioneer in RAS-mediated cancers.”
Listen at 22:50
Revolution Medicines’ valuation does not fully reflect future upside.
“a $36 billion valuation is sort of pricing out some of the upside that I think is yet to come.”
Listen at 23:07
Arasaka may reach market faster than Revolution Medicines did.
“Eraska is going to be maybe a little quicker to get to market than it had taken RevMed.”
Listen at 24:34
Arasaka’s therapy remains more than a year from market launch.
“it's still going to take them, you know, over a year and change to be able to get a therapy on the market.”
Listen at 25:05
Arasaka’s benchmark is 40% response in PDAC and 60% in NSCLC.
“the 40% for PDAC and 60% NSCLC is gonna be the benchmark for them to hit.”
Listen at 26:05
Tango’s combination achieved an 82% objective response rate.
“they were able to get an 82% objective response rate.”
Listen at 27:59
Revolution Medicines looks attractive at current prices.
“I definitely think that RevMed is looking good at these prices.”
Listen at 29:54
Statements are attributed to the speaker as said on the episode and reflect their view at the time, not PodLume's. They are not advice.
Weekly email
State of the Pod, every Monday
The week's most-discussed names and stories from podcasts, with the moments behind them. Free, five minutes, unsubscribe in one click.